clinical trial · NCT07417735
SYS6010 Versus Chemotherapy in Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma
CSPC Megalith Biopharmaceutical Co.,Ltd.·phase3·not yet recruiting·n = 436
Locally Advanced/Metastatic/Recurrent ESCCSYS6010Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel)
brief summary
This study is a randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Study of SYS6010 vs Investigator's Choice Single-Agent Chemotherapy in Locally Advanced/Metastatic/Recurrent ESCC Patients with Failure of At Least One Line of Systemic Therapy
started
Mar 18, 2026
primary completion
Dec 31, 2028
completion
Dec 31, 2029
last updated
Feb 18, 2026
official title
A Randomized, Controlled, Open-Label, Multicenter Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of SYS6010 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic/Recurrent Esophageal Squamous Cell Carcinoma Who Have Failed at Least One Line of Systemic Therapy.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol